Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated consensus interferon variant vs peginterferon alfa-2a in HBeAg-positive chronic hepatitis B
CTR20213449Phase 2Completed
- Sponsor
- Chongqing Fujin Biopharmaceutical
- Start
- Dec 2021
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated recombinant consensus interferon variant in Chronic Hepatitis B (CHB), sponsored by Chongqing Fujin Biopharmaceutical. Started Dec 2021; status: completed.
02
Drugs
pegylated recombinant consensus interferon variant
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20213449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213449.